Cell No. 4 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Cell No. 4 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

September 25, 2018

Viracta Announces Scientific Advisory Board Formation

San Diego, CA, September 25, 2018 - Viracta Therapeutics, Inc., a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, announced the formation of its inaugural Scientific Advisory Board. The SAB will serve as a strategic resource as Viracta advances therapies based on its kick & kill platform and applies its proprietary epigenetic drug, tractinostat, to enhance cancer immunotherapy.

“We are thrilled with the addition of these experts to our team of advisors,” said Ivor Royston, M.D., President and Chief Executive Officer of Viracta. “Their background and experience will be invaluable as we advance our clinical programs to address Epstein-Barr Virus- and other virus-associated malignancies. This group will also provide valuable perspective and insights as we explore opportunities to apply tractinostat in combination with a range of immunotherapy modalities to enhance their efficacy, including checkpoint inhibitor, CAR-T, CTL and TCR immunotherapies.”

The inaugural members of Viracta’s SAB include:

“The launch of Viracta’s SAB underscores our commitment to advance development of our therapeutic approach and applications of tractinostat to enhance antiviral and immunotherapies,” said Marshelle Smith Warren, M.D., VP of R&D and Chief Medical Officer at Viracta. “This group brings leading expertise on the interactions between viruses, tumors, the epigenome and immune response to guide our drug development efforts and rational expansion for applications of Viracta’s treatment platform.”

About Viracta

Viracta is a clinical-stage drug development company committed to advancing new medicines based on its unique kick & kill therapeutic approach to benefit patients with viral-associated cancers and other serious diseases.

For press or investor inquiries regarding Viracta, please call (858) 400-8470, or email info@viracta.com. For additional information see www.viracta.com.

September 25, 2018

Viracta Announces Scientific Advisory Board Formation

San Diego, CA, September 25, 2018 - Viracta Therapeutics, Inc., a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, announced the formation of its inaugural Scientific Advisory Board. The SAB will serve as a strategic resource as Viracta advances therapies based on its kick & kill platform and applies its proprietary epigenetic drug, tractinostat, to enhance cancer immunotherapy.

“We are thrilled with the addition of these experts to our team of advisors,” said Ivor Royston, M.D., President and Chief Executive Officer of Viracta. “Their background and experience will be invaluable as we advance our clinical programs to address Epstein-Barr Virus- and other virus-associated malignancies. This group will also provide valuable perspective and insights as we explore opportunities to apply tractinostat in combination with a range of immunotherapy modalities to enhance their efficacy, including checkpoint inhibitor, CAR-T, CTL and TCR immunotherapies.”

The inaugural members of Viracta’s SAB include:

“The launch of Viracta’s SAB underscores our commitment to advance development of our therapeutic approach and applications of tractinostat to enhance antiviral and immunotherapies,” said Marshelle Smith Warren, M.D., VP of R&D and Chief Medical Officer at Viracta. “This group brings leading expertise on the interactions between viruses, tumors, the epigenome and immune response to guide our drug development efforts and rational expansion for applications of Viracta’s treatment platform.”

About Viracta

Viracta is a clinical-stage drug development company committed to advancing new medicines based on its unique kick & kill therapeutic approach to benefit patients with viral-associated cancers and other serious diseases.

For press or investor inquiries regarding Viracta, please call (858) 400-8470, or email info@viracta.com. For additional information see www.viracta.com.